Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

Not Applicable

Completed

• Conditions: Mycobacterium Avium-intracellulare Infection; HIV Infections

• Registration Number: NCT00002267
• Lead Sponsor: Pharmacia

Brief Summary

The primary objective of this trial is to assess the safety and the relative benefit of rifabutin monotherapy in preventing or delaying the incidence of Mycobacterium avium complex (MAC) bacteremia in AIDS patients with CD4 counts less than or equal to 200, as compared to placebo, and to assess if survival is prolonged in patients who receive rifabutin prophylaxis.

Detailed Description

Not available

Study Timeline

• Status Verified: 1992-03
• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 750

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (43)

Maricopa County Med Ctr; 🇺🇸 Phoenix, Arizona, United States

East Bay AIDS Ctr; 🇺🇸 Berkeley, California, United States

Pacific Oaks Med Group; 🇺🇸 Beverly Hills, California, United States

AIDS Community Research Consortium; 🇺🇸 Redwood City, California, United States

HIV Research Group; 🇺🇸 San Diego, California, United States

Dr Larry A Waites; 🇺🇸 San Francisco, California, United States

Saint Francis Mem Hosp / HIV Care; 🇺🇸 San Francisco, California, United States

Dr Marcus Conant; 🇺🇸 San Francisco, California, United States

San Francisco Veterans Administration Med Ctr; 🇺🇸 San Francisco, California, United States

Dr Marshall Kubota; 🇺🇸 Santa Rosa, California, United States

Scroll for more (33 remaining)